At PharmAsia Summit, VCs Discuss Financing Innovation in Asia
This article was originally published in The Pink Sheet Daily
Executive Summary
As returns falter in the U.S., VC firms are finding that infrastructure investments overseas are opening up uncharted territory for the life sciences industry.
You may also be interested in...
Corporate Venture Capital’s Role In Developing Next-Generation Biologics: An Interview With Takeda Research Investment’s Graeme Martin (part 2 of 2)
With private-equity investments in early-stage financing gone, corporate venture needs to support these opportunities, “because if you don’t, the biotechnology industry is going to disappear. It’s just going to dry up,” Martin maintains.
Takeda Research Investment’s Graeme Martin on Corporate Venture Capital’s New Role In Developing Next-Generation Biologics: An Interview With PharmAsia News (Part 1 of 2)
Attend any industry conference these days, and a general theme will appear that venture capital is not as readily available as it once was. A dearth of venture funding, particularly for early-stage research, could impact long-term future development of emerging biotechnologies. Graeme Martin, president of Takeda's corporate venture arm Takeda Research Investment, talks with PharmAsia News about the changing scope of corporate venture capital in this atmosphere as well as the role of CVC in helping inform companies' development strategies.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.